UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - NEOLEUKIN THERAPEUTICS INC ownership

Quarter-by-quarter ownership
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC ownership history of NEOLEUKIN THERAPEUTICS INC
ValueSharesWeighting
Q3 2021$74,758,000
-21.7%
10,3400.0%0.00%
Q2 2021$95,438,000
-54.6%
10,340
-30.6%
0.00%
Q4 2020$210,090,00014,9000.00%
Other shareholders
NEOLEUKIN THERAPEUTICS INC shareholders Q2 2024
NameSharesValueWeighting ↓
Opaleye Management Inc. 1,047,300$5,048,0001.07%
ACT CAPITAL MANAGEMENT, LLC 212,500$1,024,0000.74%
Redmile Group, LLC 3,490,835$16,826,0000.38%
Kynam Capital Management, LP 147,000$709,0000.38%
EcoR1 Capital, LLC 860,619$4,148,0000.13%
Baker Brothers Advisors 3,821,740$18,421,0000.09%
GSA CAPITAL PARTNERS LLP 130,899$631,0000.08%
Sio Capital Management, LLC 38,312$185,0000.06%
Highland Private Wealth Management 46,999$227,0000.03%
XTX Topco Ltd 10,018$48,0000.03%
View complete list of NEOLEUKIN THERAPEUTICS INC shareholders